CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sorrento Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sorrento Therapeutics Inc
4955 Directors Place
Phone: (858) 203-4100p:858 203-4100 SAN DIEGO, CA  92121  United States Ticker: SRNE SRNE
This company's Plan of Liquidation went into effect on 4/10/2024
Business Summary
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations
7372 Prepackaged software
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer Henry H.Ji 59 1/1/2022 1/1/2006
Lead Independent Director DormanFollowwill 58 8/1/2020 10/1/2017
Director Kim D.Janda 64 8/1/2020 4/1/2012
3 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Concortis Biosystems, Corp. 11760 sorrento valley, suite R San Diego CA United States
ACEA Therapeutics, Inc. 9924 Mesa Rim Road San Diego CA United States
Smartpharm Therapeutics, Inc. 650 E. Kendall Street Cambridge MA United States
SCILEX Pharmaceuticals, Inc. 301 Lindenwood Drive Malvern PA United States
Scintilla Pharmaceuticals, Inc. 7 Switchbud Place, Suite 192-513 The Woodlands TX United States

Business Names
Business Name
ACEA Therapeutics, Inc.
Adnab, Inc.
Ark Animal Health, Inc.
21 additional Business Names available in full report.

General Information
Number of Employees: 949 (As of 12/31/2022)
Outstanding Shares: 551,281,154 (As of 8/8/2023)
Shareholders: 197
Stock Exchange: OTC
Federal Tax Id: 330344842
Fax Number: (858) 203-4028
Email Address: info@sorrentotherapeutics.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 17, 2024